semaglutide approved for mash π΄We now have two FDA-approved drugs MASLD/MASH: πΈ Resmetirom (oral, THR-Ξ² agonist) πΉ (weekly SC, GLP-1 RA) side-by-side comparison, courtesy of @rabataller #MASLD #MASH #FattyLiver @_ILTS_ @EASLedu @AASLDtweets @novonordisk Resmetirom and GLP-1 agonists for
Description
without HF: HR 0.44

Made with natural ingredients to soothe and balance your gut, its the perfect companion for anyone using GLP-1 medications or looking to feel their best every day

Completion of the trials main phase is expected in September 2025, and the 52-week extension (in which participants and investigators remain blinded to treatment assignment) will continue to October 2026

Conclusion The formulation could potentially be an one-month sustained-release injectable therapy with the expectation of anti-obesity effect

Would you like to enhance your body and feel more confident

Initial titration format 2-4 weeks
